News

Flagship Biosciences ActionAssays Deliver Actionable Data to Drive Immuno-Oncology Decisions

Back to News

Comprehensive catalog of assays advance biomarker programs

Westminster, CO, January 16, 2018 – Flagship Biosciences has introduced a new menu of services to help drug developers more confidently define their path to success. ActionAssaysTM is a comprehensive catalog of brightfield immunohistochemistry (IHC) assays that provide actionable data to define and advance biomarker programs.

ActionAssays includes more than 100 singleplex and multiplex assays for standard and emerging immuno-oncology targets, such as: CD3, CD4, CD8, CD30, CD68, FoxP3, OX40, IDO-1, PD-1, and PD-L1. Clinically validated assays for diagnostic use and custom assay development are also available.

“ActionAssays provide an affordable way for drug developers to generate new hypotheses, with the flexibility to expand and refine endpoints to meet long-term development goals,” says Trevor Johnson, Flagship General Manager and COO. “Flagship strives to be the partner of choice for drug developers from research to clinical trials and companion diagnostics.”

As the only fully integrated, full-service image analysis and CLIA-certified lab service in the U.S., Flagship combines the expertise of pathologists, scientists, histologists and image analysts to generate and interpret contextual tissue data and answer the most challenging pathology questions. A more robust evaluation of slides is also available using Flagship’s Computational Tissue Analysis (cTA®) platform to amplify possible endpoints from manual pathology.

Learn more about how ActionAssays can help advance drug development decisions with confidence.

Media Contact:
Amy Shannon
VP, Sales & Marketing
ashannon@flagshipbio.com
303.608.9008

Share this Post: